Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anaptysbio Inc

23.75
-0.1300-0.54%
Post-market: 23.60-0.1500-0.63%16:20 EDT
Volume:212.76K
Turnover:5.07M
Market Cap:697.79M
PE:-4.96
High:24.13
Open:23.65
Low:23.51
Close:23.88
Loading ...

AnaptysBio Inc - Top-Line Week 12 Phase 2 Ulcerative Colitis Data for Rosnilimab Expected in Q4 2025

THOMSON REUTERS
·
12 Feb

Anaptys Announces Rosnilimab Achieved Positive Results in Ra Phase 2B Trial and Highest Ever Reported Cdai Lda Response Over 6 Months

THOMSON REUTERS
·
12 Feb

BRIEF-Anaptys To Announce Top-Line Data From Phase 2B Trial Of Rosnilimab, A PD-1 Depleter And Agonist, In Rheumatoid Arthritis

Reuters
·
12 Feb

Anaptys to Announce Top-Line Data From Phase 2B Trial of Rosnilimab, a Pd-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

THOMSON REUTERS
·
12 Feb

Wedbush Sticks to Its Buy Rating for AnaptysBio (ANAB)

TIPRANKS
·
07 Feb

Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago

Simply Wall St.
·
05 Feb

AnaptysBio Initiated at Outperform by Wolfe Research

Dow Jones
·
05 Feb

Truist Securities Initiates Coverage on AnaptysBio With Outperform Rating, $25 Price Target

MT Newswires Live
·
04 Feb

AnaptysBio initiated with an Outperform at Wolfe Research

TIPRANKS
·
04 Feb

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire
·
04 Feb

Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab

MT Newswires Live
·
03 Feb

BRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab

Reuters
·
03 Feb

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an Il-36R Antagonist

THOMSON REUTERS
·
03 Feb

Vanda Pharmaceuticals Inc: Vanda Expects to Immediately Begin Preparing Bla and Maa Applications for US and EU

THOMSON REUTERS
·
03 Feb

Vanda Pharmaceuticals Inc: Anaptys to Receive $15 Mln From Vanda, Comprised of a $10 Mln Upfront Payment and $5 Mln for Existing Drug Supply

THOMSON REUTERS
·
03 Feb

Vanda Pharmaceuticals Inc: Anaptys to Receive a 10% Royalty on Global Net Sales of Imsidolimab

THOMSON REUTERS
·
03 Feb

AnaptysBio (ANAB) Receives a Buy from TD Cowen

TIPRANKS
·
29 Jan

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Zacks
·
27 Jan

Leerink Partners Remains a Buy on AnaptysBio (ANAB)

TIPRANKS
·
20 Jan

Big Biotech Fund Bought a Stock That Surged, and a Loser -- Barron's

Dow Jones
·
18 Jan